DTIL
Price
$4.13
Change
-$0.07 (-1.67%)
Updated
Jul 1, 04:59 PM (EDT)
Capitalization
45.79M
NTLA
Price
$9.89
Change
+$0.51 (+5.44%)
Updated
Jul 1, 04:59 PM (EDT)
Capitalization
970.58M
30 days until earnings call
Interact to see
Advertisement

DTIL vs NTLA

Header iconDTIL vs NTLA Comparison
Open Charts DTIL vs NTLABanner chart's image
Precision BioSciences
Price$4.13
Change-$0.07 (-1.67%)
Volume$1.21K
Capitalization45.79M
Intellia Therapeutics
Price$9.89
Change+$0.51 (+5.44%)
Volume$268.1K
Capitalization970.58M
DTIL vs NTLA Comparison Chart in %
Loading...
DTIL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DTIL vs. NTLA commentary
Jul 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DTIL is a Hold and NTLA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 02, 2025
Stock price -- (DTIL: $4.20 vs. NTLA: $9.38)
Brand notoriety: DTIL and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DTIL: 55% vs. NTLA: 57%
Market capitalization -- DTIL: $45.79M vs. NTLA: $970.58M
DTIL [@Biotechnology] is valued at $45.79M. NTLA’s [@Biotechnology] market capitalization is $970.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $306.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DTIL’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • DTIL’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, NTLA is a better buy in the long-term than DTIL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DTIL’s TA Score shows that 5 TA indicator(s) are bullish while NTLA’s TA Score has 6 bullish TA indicator(s).

  • DTIL’s TA Score: 5 bullish, 5 bearish.
  • NTLA’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than DTIL.

Price Growth

DTIL (@Biotechnology) experienced а -7.28% price change this week, while NTLA (@Biotechnology) price change was +1.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.51%. For the same industry, the average monthly price growth was +32.88%, and the average quarterly price growth was +3.93%.

Reported Earning Dates

DTIL is expected to report earnings on May 15, 2025.

NTLA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-0.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($971M) has a higher market cap than DTIL($45.8M). DTIL YTD gains are higher at: 10.236 vs. NTLA (-19.554). DTIL has higher annual earnings (EBITDA): -16.57M vs. NTLA (-530.8M). NTLA has more cash in the bank: 504M vs. DTIL (77.2M). DTIL has less debt than NTLA: DTIL (29.7M) vs NTLA (119M). DTIL has higher revenues than NTLA: DTIL (51.1M) vs NTLA (45.6M).
DTILNTLADTIL / NTLA
Capitalization45.8M971M5%
EBITDA-16.57M-530.8M3%
Gain YTD10.236-19.554-52%
P/E Ratio4.53N/A-
Revenue51.1M45.6M112%
Total Cash77.2M504M15%
Total Debt29.7M119M25%
FUNDAMENTALS RATINGS
DTIL vs NTLA: Fundamental Ratings
DTIL
NTLA
OUTLOOK RATING
1..100
504
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
27
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
8562
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (27) in the Biotechnology industry is in the same range as DTIL (31). This means that NTLA’s stock grew similarly to DTIL’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DTIL (100). This means that NTLA’s stock grew similarly to DTIL’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as DTIL (97). This means that NTLA’s stock grew similarly to DTIL’s over the last 12 months.

NTLA's Price Growth Rating (62) in the Biotechnology industry is in the same range as DTIL (85). This means that NTLA’s stock grew similarly to DTIL’s over the last 12 months.

NTLA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as DTIL (100). This means that NTLA’s stock grew similarly to DTIL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DTILNTLA
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 26 days ago
78%
Bullish Trend 8 days ago
77%
Declines
ODDS (%)
Bearish Trend 6 days ago
89%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 5 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
DTIL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LADR10.750.11
+1.03%
LADDER CAPITAL Corp
GD291.660.92
+0.32%
General Dynamics Corp
PSTL14.73-0.19
-1.27%
Postal Realty Trust
FLS52.35-1.29
-2.40%
Flowserve Corp
LFWD0.64-0.03
-3.76%
Lifeward Ltd